Abstract
The incidence of meningococcal disease peaks during the neonatal years and again during the adolescent years. Most adolescent cases are vaccine preventable using the current tetravalent meningococcal vaccines. In February 2005 the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention recommended routine immunization with the tetravalent conjugate meningococcal vaccine of all 11–12-year-olds with the interim recommendation including all 14–15-year-olds and special targeted populations to include incoming college freshmen living in dormitories military recruits certain travelers microbiologists working with Neisseria meningitidis and those with terminal complement component deficiencies and asplenia. The Society for Adolescent Medicine strongly supports the ACIP recommendations and encourages vaccination of all youth who are 11 years of age or greater with the tetravalent conjugate meningococcal vaccine. (excerpt)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
